- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 92,200 | 16.07.24 13:58:34 | -0,100 | -0,11% | 0,000 | 0,000 | 92,270 | 92,300 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 998,000 | 16.07.24 08:10:55 | -11,800 | -1,18% | 0,000 | 0,000 | 988,200 | 1.000,000 |
